The core R&D team is made of industrial and academic experts in molecular mechanisms of regulated cell death and related pathogenesis in human diseases. In its journey toward developing innovative medicines, the Company has also recruited a number of industrial veterans in Medicinal Chemistry, Pharmacology, Toxicology, DMPK, CMC, Clinical Studies, etc.
Cell death programs are critical for the maintenance of organismal homeostasis and the control of immune responses. Regulated cell death such as necroptosis, pyroptosis, and ferroptosis are associated with many major human diseases . Focusing on molecular targets associated with regulated cell death, Accro Bioscience (Suzhou) Limited has developed multiple innovative compounds for therapeutic intervention of inflammatory and autoimmune diseases and cancer.
The company has a robust drug discovery portfolio with innovative compounds in various stages spanning from lead optimization to pre-clinical development.